Initial Public Offerings:

  • Citigroup Global Markets as lead underwriter in Arsanis, Inc’s US$46 million initial public offering 
  • Cowen and Company as lead underwriter in Regado Biosciences, Inc.’s US$45 million initial public offering
  • Cowen and Company as lead underwriter in Nivalis Therapeutics, Inc.’s US$89 million initial public offering 
  • JMP Securities as lead underwriter in Summit Therapeutics PLC’s (UK) US$35 million initial public offering 
  • J.P. Morgan and Stifel as joint global coordinators and joint book-running managers in RenalytixAI plc (UK) US$85 million initial public offering 
  • J.P. Morgan as lead underwriter in G1 Therapeutics, Inc.’s US$105 million initial public offering 
  • J.P. Morgan as lead underwriter in Intrexon Corporation’s US$160 million initial public offering
  • Ladenburg Thalmann as lead underwriter in Immunome, Inc.’s US$45 million initial public offering 
  • Ladenburg Thalmann as sole underwriter in Krystal Biotech, Inc.’s US$30 million initial public offering 
  • Piper Jaffray & Co. as lead underwriter in Innocoll AG’s (Germany) US$60 million initial public offering 
  • Piper Jaffray & Co. as lead underwriter in Argos Therapeutics’ US$45 million initial public offering
  • SVB Leerink as lead underwriter in Centogene N.V.’s (The Netherlands) US$64 million initial public offering

Follow-On Offerings:

  • BofA Securities as lead underwriter in BeyondSpring Inc.’s US$86 million follow-on offering
  • BTIG as sole underwriter in two “bought deals” for Cerus Corporation
  • Cowen and Company as lead underwriter in Protara Inc.’s US$150 million concurrent public offering of common and preferred stock 
  • Credit Suisse as lead underwriter in Centogene N.V.’s (The Netherlands) US$50 million primary and secondary public offering 
  • Deutsche Bank Securities Inc. as lead underwriter of Orient-Express Hotels Ltd.’s three public offerings raising aggregate gross proceeds of US$400 million
  • An American multinational investment bank and financial services company as lead underwriter in Sarepta Therapeutics, Inc.’s US$325 million follow-on offering 
  • An American multinational investment bank and financial services company as lead underwriter in Krystal Biotech, Inc.’s US$100 million follow-on offering 
  • An American multinational investment bank and financial services company as lead underwriter in Sarepta Therapeutics, Inc.’s US$500 million follow-on offering 
  • Jefferies as lead underwriter in Solutia Inc.’s US$160 million follow-on offering 
  • JMP Securities, as lead underwriter in Flamel Technologies, S.A.’s (France) US$105 million follow-on offering 
  • JMP Securities as lead underwriter in Intrexon Corporation’s US$200 million follow-on offering 
  • J.P. Morgan as lead underwriter in OvaScience, Inc.’s US$125 million follow-on offering 
  • J.P. Morgan as lead underwriter in G1 Therapeutics, Inc.’s US$210 million follow-on offering 
  • J.P. Morgan as lead underwriter in NPS Pharmaceuticals, Inc.’s US$87 million follow-on offering 
  • Morgan Stanley as lead underwriter in a US$162 million public offering by existing shareholders of Horizon Pharma, Inc.
  • Morgan Stanley as lead underwriter in Innocoll AG’s (Germany) US$40 million follow-on offering 
  • Piper Jaffray & Co. as lead underwriter in Itamar Medical Ltd.’s (Israel) US$40 million public offering 
  • Piper Jaffray & Co. as sole underwriter in Global Eagle Entertainment Inc.’s US$190 million follow-on offering 
  • William Blair & Company as lead underwriter in Viking Therapeutics, Inc.’s US$175 million follow-on offering 

Alternative Transactions:

  • Cowen and Company, as lead placement agent in Invitae Corporation’s US$275 million PIPE to finance its acquisition of Archer DX
  • Cowen and Company, as lead placement agent in Horizon Pharma Inc.’s US$150 million five percent convertible note offering
  • Deutsche Bank Securities as placement agent in a US$600 million registered direct offering for The St. Joe Company
  • Deutsche Bank Securities Inc. as lead placement agent in Smith & Wesson Holding Corporation’s two registered direct offerings 
  • Jefferies as lead placement agent in TFF Pharmaceuticals, Inc.’s US$26 million PIPE 
  • Piper Sandler & Co. as sole placement agent in U.S. Well Services, Inc.’s US$21 million PIPE